Prognostic role of inflammatory biomarkers from peripheral blood and clinical factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra-223) (BIO-Ra-223 study).

被引：0
|
作者：
Rebuzzi, Sara Elena
Bauckneht, Matteo
Signori, Alessio
Frantellizzi, Viviana
Rizzini, Elisa Lodi
Mascia, Manlio
Lavelli, Valentina
Stazza, Maria Lina
Licari, Maria
Donegani, Maria Isabella
Ponzano, Marta
Cavallini, Letizia
Laghi, Viola
Cindolo, Luca
Costa, Renato Patrizio
Spanu, Angela
Rubini, Giuseppe
Monari, Fabio
De Vincentis, Giuseppe
Fornarini, Giuseppe
机构：
[1] Univ Genoa, Med Oncol Unit 1, IRCCS Osped Policlin San Martino, Dept Internal Med & Med Specialties DiMI, Genoa, Italy
[2] IRCCS Osped Policlin San Martino, Nucl Med Unit, Genoa, Italy
[3] Sapienza Univ Rome, Dept Mol Med, Rome, Italy
[4] IRCCS Azienda Osped Univ Bologna, Radiat Oncol, Bologna, Italy
[5] Spirito Santo Hosp, Nucl Med Unit, Pescara, Italy
[6] Univ Bari Aldo Moro, Dept Nucl Med, Bari, Italy
[7] Univ Sassari, Dept Med Surg & Expt Sci, Nucl Med Unit, Sassari, Italy
[8] Univ Palermo, Biomed Dept Internal & Specialist Med, Nucl Med Unit, Palermo, Italy
[9] Univ Genoa, Dept Hlth Sci DISSAL, IRCCS Osped Policlin San Martino, Nucl Med, Genoa, Italy
[10] Univ Genoa, Dept Hlth Sci DISSAL, Genoa, Italy
[11] Alma Mater Studiorum Bologna Univ, Dept Expt Diagnost & Specialty Med, IRCCS Azienda Osped Univ Bologna, Radiat Oncol, Bologna, Italy
[12] Villa Stuart Private Hosp, Dept Urol, Rome, Italy
[13] Sapienza Univ Rome, Dept Radiol Sci Oncol & Anat Pathol, Rome, Italy
[14] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, Genoa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17026
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The prognostic role of inflammatory indices from peripheral blood and clinical factors in metastatic castration-resistant prostate cancer (mCRPC) patients treated with Radium-223 (BIO-Ra-223 study)
    Donegani, M.
    Rebuzzi, S. E.
    Ponzano, M.
    Bauckneht, M.
    Frantellizzi, V.
    Rizzini, E. Lodi
    Mascia, M.
    Lavelli, V.
    Gaudiano, A.
    Stazza, M. L.
    Licari, M.
    Murianni, V.
    Signori, A.
    Cavallini, L.
    Laghi, V.
    Cindolo, L.
    Costa, R. P.
    Spanu, A.
    Rubini, G.
    Monari, F.
    De Vincentis, G.
    Fornarini, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S312 - S313
  • [2] Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
    Palmedo, H.
    Eschmann, S.
    Werner, A.
    Selinski, I.
    Moellers, M-O.
    Kalinovsky, J.
    Benson, A.
    Poeppel, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 336 - 336
  • [3] Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
    Palmedo, H.
    Ahmadzadehfar, H.
    Eschmann, S.
    Selkinski, I.
    Straube, F.
    Niesen, A.
    Schoenberger, J.
    Barsegian, V.
    Liepe, K.
    Mottaghy, F. M.
    Guan, R.
    Pinkert, J.
    Buetikofer, S.
    Herrmann, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S641 - S641
  • [4] Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).
    Alonzi, Roberto
    Parker, Chris C.
    Tunariu, Nina
    Koh, Dow-Mu
    Staffurth, John
    Blackledge, Matthew D.
    Padhani, Anwar R.
    Tree, Alison
    Stidwill, Helen
    Finch, Jessica
    Chatfield, Peter
    Perry, Sophie
    Tovey, Holly
    Hall, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
    Hijab, A.
    Tunariu, N.
    Tovey, H.
    Alonzi, R.
    Tree, A.
    Staffurth, J.
    Blackledge, M.
    Padhani, A. R.
    Stidwill, H.
    Finch, J.
    Chatfield, P.
    Perry, S.
    Koh, D-M.
    Hall, E.
    Parker, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S539 - S539
  • [6] Safety outcomes and pain responses in the REASSURE observational study of radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Conti, Peter
    George, Saby
    Tomaszewski, Jeffrey
    Song, Daniel
    Harshman, Lauren
    Nordquist, Luke
    Sandstrom, Per
    Bayh, Inga
    Babajanyan, Svetlana
    Sartor, Oliver
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [7] Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP).
    Heidenreich, Axel
    Gillessen, Silke
    Heinrich, Daniel
    Keizman, Daniel
    O'Sullivan, Joe M.
    Carles, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [8] Clinical outcomes of a Dutch prospective observational registry of metastatic castration resistant prostate cancer (mCRPC) patients treated with radium-223 (Ra-223).
    Louhanepessy, Rebecca
    Badrising, Sushil
    van der Noort, Vincent
    Coenen, Jules L. L. M.
    Hamberg, Paul
    Beeker, Aart
    Wagenaar, Nils
    Lam, Marnix G. E. H.
    Celik, Filiz
    Loosveld, Olaf
    Oostdijk, Ad
    Zuetenhorst, Johanna Maria
    Vegt, Erik
    Zwart, Wilbert
    Bergman, Andre M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [9] Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC)
    Higano, Celestia S.
    Saad, Fred
    Sartor, A. Oliver
    Miller, Kurt
    Conti, Peter
    George, Daniel J.
    Sternberg, Cora N.
    Shore, Neal D.
    Sade, Juan Pablo
    Bellmunt, Joaquim
    Smith, Matthew Raymond
    Logothetis, Christopher
    Verholen, Frank
    Kalinovsky, Jan
    Bayh, Inga
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [10] The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)
    Matteo Bauckneht
    Sara Elena Rebuzzi
    Alessio Signori
    Viviana Frantellizzi
    Veronica Murianni
    Elisa Lodi Rizzini
    Manlio Mascia
    Valentina Lavelli
    Maria Isabella Donegani
    Marta Ponzano
    Angela Gaudiano
    Maria Lina Stazza
    Maria Licari
    Letizia Cavallini
    Viola Laghi
    Luca Cindolo
    Martina Maggi
    Alessandro Sciarra
    Paolo Mammucci
    Gianmario Sambuceti
    Renato Patrizio Costa
    Angela Spanu
    Giuseppe Rubini
    Fabio Monari
    Giuseppe De Vincentis
    Giuseppe Fornarini
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 1063 - 1074
12345